Altimmune (NASDAQ: ALT) revenue
Altimmune reported revenue of $0.0m for fiscal 2025, 105.0% more than in fiscal 2024 ($0.0m). Since fiscal 2016 its revenue has fallen by 98.7%, an average decline of 38.5% a year.
Altimmune's best year of the last 10 was fiscal 2017. The biggest drop was in fiscal 2024, −95.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | +105.0% | −$94.5m | −230,461.0% |
| 2024 | $0.0m | −95.3% | −$103.2m | −515,860.0% |
| 2023 | $0.4m | — | −$95.9m | −22,518.5% |
| 2022 | −$0.1m | −101.5% | −$87.7m | — |
| 2021 | $4.4m | −46.1% | −$96.9m | −2,197.6% |
| 2020 | $8.2m | +41.1% | −$54.8m | −669.5% |
| 2019 | $5.8m | −43.8% | −$21.5m | −370.0% |
| 2018 | $10.3m | −3.8% | −$42.8m | −414.6% |
| 2017 | $10.7m | +231.8% | −$52.0m | −484.7% |
| 2016 | $3.2m | — | −$11.1m | −342.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Altimmune revenue compared with its sector
By revenue for its latest fiscal year, Altimmune ranks 401st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Altimmune, 105.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 399th | Connect Biopharma | $0.1m | −99.8% |
| 400th | Avalo Therapeutics | $0.1m | −86.6% |
| 401st | Altimmune | $0.0m | 105.0% |
| 402nd | Lyell Immunopharma | $0.0m | −41.0% |
| 403rd | Amylyx Pharmaceuticals | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Altimmune
- How much revenue did Altimmune make in fiscal 2025?
- Altimmune reported revenue of $0.0m for fiscal 2025, compared with $0.0m in fiscal 2024.
- How much has the revenue of Altimmune fallen?
- Between fiscal 2016 and fiscal 2025 it went from $3.2m to $0.0m: 98.7% less, an average decline of 38.5% a year.
- What was the best year for revenue at Altimmune?
- Of its last 10 fiscal years, fiscal 2017, with $10.7m.
- Where does Altimmune rank in its sector by revenue?
- It ranks 401st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Altimmune come from?
- From the annual report (Form 10-K) that Altimmune files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Altimmune files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Altimmune: the Altimmune page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.